Discussion  by unknown
Lorusso et al Acquired Cardiovascular Disease20. ten Brinke EA, Klautz RJ, Tulner SA, Verwey HF, Bax JJ, Delgado V, et al. Clin-
ical and functional effects of restrictive mitral annuloplasty at mid-term follow up
in heart failure patients. Ann Thorac Surg. 2010;90:1913-21.
21. Hung J, Papakostas L, Tahta SA, Hardy BG, Bollen BA, Duran CM, et al. Mech-
anism of recurrent ischemic mitral regurgitation. Circulation. 2004;110:
II85-90.
22. Calafiore AM, Di Mauro M, Gallina S, Di Gianmarco G, Iaco AL, Teodori G,
et al. Mitral valve surgery for chronic ischemica mitral regurgitation. Ann Thorac
Surg. 2004;77:1989-97.
23. De Bonis M, Lapenna E, Verzini A, La Canna G, Grimaldi A, Torracca L, et al.
Recurrence of mitral regurgitation parallels the absence of left ventricular remod-
eling after mitral repair in advanced dilated cardiomyopathy. Ann Thorac Surg.
2008;85:932-9.
24. Athanasiou T, Chow A, Rao C, Aziz O, Siannis F, Ali A, et al. Preservation of the
mitral valve apparatus: evidence synthesis and critical reappraisal of surgical
techniques. Eur J Cardiothorac Surg. 2008;33:391-401.
25. Perrault LP, Moskowitz AJ, Kron IL, Acker MA, Miller MA, Horvath KA, et al.
Optimal surgical management of severe ischemic mitral regurgitation: to repair
or to replace? J Thorac Cardiovasc Surg. 2012;143:1396-403.A
C
DDiscussion
Dr Irving Kron (Charlottesville, Va). I must say I have a con-
flict of interest in that I am a primary investigator for the Cardio-
thoracic Surgical Network.
I would like to congratulate the authors on an outstanding paper.
They have been accurate and clear and discussed the issues with
such an analysis. They have done a database study of>1000 pa-
tients with CIMR. This is a retrospective study with propensity
matching. The findings were interesting. Patients with MVR had
a 3% mortality versus 5% for MVP, and this was not significant.
The 8-year survival was exactly the same. Based on these findings,
it would seem that MVR is certainly a reasonable strategy.
There are, however, difficulties with this assessment. First and
foremost, this is a retrospective study with little standardization
of the procedures or choice of repair versus replacement. In the re-
placement group, the majority of patients did not have chordal
sparing of both leaflets. The majority of patients were followed
less than 5 years, so prosthetic failure cannot truly be analyzed
at this point. But bottom line, this suffers all the issues of any ret-
rospective study, although this is an excellent attempt to give us an
answer to this clinical problem.
The Network study is a randomized study, and we have just
closed enrollment of 250 patients randomized to mitral repair vs
replacement. Of course, the issue is as the authors stated: Is repair
less risky versus the issues of later recurrence? So I believe the ran-
domized trial may give us an answer to this, but certainly not the
long-term follow-up at this point. I have two questions for the
authors.
The first is, could they predict which patients who had repairs
were likely to recur? They have a great data set. The second ques-
tion is whether, with longer follow-up, will there be more reopera-
tions for the prosthetic replacement group? Thank you very much
for an excellent effort.
Dr Parolari. Thank you so much, Dr Kron, for your questions.
For the first one, up to now the core lab is still investigating the
problem of prediction of mitral valve recurrence. The problem is
that this is a retrospective study, and the earliest cases date back
to about 15 years, and also the echocardiographic variables that
were collected in earlier cases were different than the ones thatThe Journal of Thoracic and Cawere collected in later ones. We know that this is one of the next
tasks to be addressed, but up to now I don’t have any data about
that.
The second question is the problem of reoperation on biopros-
thetic valves. I think the problem raised in our paper is the follow-
ing one.We have selected somehow lower risk patients becausewe
excluded reoperations, we excluded emergency cases, and we had
high survival rates. I mean both in the replacement and in the re-
paired valve groups, the estimated survival at 8 years was around
80%. If so, many patients with a bioprosthetic valve survive in the
long term, and we know that bioprosthetic valves may have prob-
lems at longer follow-up times. This is going to be an issue. And
probably we will see that, in the future, when longer follow-up
times are available, although up until now, the difference between
a patient who got a mechanical prosthesis and a patient who got
a bioprosthesis in terms of reoperation was not statistically
different.
Dr John D. Puskas (Atlanta, Ga). Thank you for your presen-
tation. You have really tackled a difficult problem and applied
a careful analysis of a large data set to that problem. One of the
challenges that Dr Kron mentioned is that this is a retrospective
study. One of the points of entry of bias into a retrospective study
is patient exclusion. You chose to exclude patients who left the
hospital and left the operating room with residual mitral regurgita-
tion after mitral repair for CIMR. If your study is to guide decision
making by surgeons, it seems to me that the decision is made well
prior to hospital discharge; the decision is made, in fact, prior to or
in the operating room whether to repair or replace the valve. Why
did you exclude patients who had an imperfect repair from your
analysis?
Dr Parolari. First of all, we excluded patients who had>1þ
grade mitral regurgitation at follow-up. We decided to do that be-
cause it is our practice, at least in past years, to leave no more
than 1þMR, and we don’t leave 2þMR or higher degrees if there
is not a good reason. Another reason why we excluded patients
with>1þMR is because many people are discussing the problem
concerning what group of patients to be compared. Some people
say—and even Dr Bolling, whom I see here, was already saying
that—that, in case of CIMR, you don’t have 2 groups to compare,
but you have 3. The first one is a good repair, the second is a bad
repair, and the third one is MVR. So we wanted to exclude the
worst repairs and just to compare only the good repairs with MVR.
Dr Steven F. Bolling (Ann Arbor, Mich). A very nice study on
a very vexing problem. You really have 2 groups. You have re-
placement and repair, and you must have 2 subgroups in your re-
pair group. Seventy-five percent of those patients got a good
repair and 25% got a bad repair with residual and recurrent MR,
and yet you blend them together to analyze their survival. That
can’t be valid. The 75% who had a good repair probably do better,
and the 25% bad repair dragged the survival average back down to
the same as replacement.
I have 2 questions for you. Reflecting on what Dr Kron said, in
the group of bad repairs, the 25%, did you identify anything that
led to a bad repair? And also, did you do analysis on these patients
in terms of their initial LV size, which may be a far more important
indicator of their long-term outcome as opposed to ejection
fraction?
Thank you. Very nice study.rdiovascular Surgery c Volume 145, Number 1 137
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DDr Parolari. Thank you for your question. First of all, con-
cerning LV diameters and LV dimensions, in the beginning, the
LV end systolic diameter mean was 56 mm in the repair group
and 59 mm in the replacement group. However, the end diastolic
volume was 117 mL in both groups. We do not have, up to now,
predictors concerning the results of repairs. It was difficult for us
to decide what was a good repair and a bad repair at the begin-
ning because we were working on retrospective data and we just
could go back to the chart. So it is very difficult for us to answer
the question.
Dr Robert A. Dion (Genk, Belgium). I would like to insist on
the fact that when one attacks such a population one has to qualify
it. I mean, there is for sure a group of patients with preoperative LV
dimensions and LV volumes who are doing much better with 1 of
the 2 solutions. For instance, I believe that if the preoperative LV
end diastolic diameter much exceeds 65 mm, the patient is proba-
bly better off even with a replacement.
What I miss in your paper is that you should not only classify
the patients according to mitral valve repair versus replacement,
but qualify them according to the preoperative dimensions,APPENDIX 1. Preoperative demographic, clinical, and echocardiographic
Variable Repair (n ¼ 708)
Age, y; mean  SD 65.8  9.1
Sex, male/female; n (%) 537/171 (75.8/24.2)
BSA, kg/m2; mean  SD 1.79  0.2
NYHA functional class; mean  SD 2.5  1.1
EuroSCORE; mean  SD 13.5  3.4
Family history, n (%) 413 (58.3)
Hypertension, n (%) 354 (50.0)
Diabetes, n (%) 243 (34.3)
COPD, n (%) 147 (20.7)
CRD, n (%) 183 (25.8)
CVD, n (%) 65 (9.1)
PVD, n (%) 26 (3.6)
AF, n (%) 77 (10.8)
Pulmonary hypertension, n (%) 70 (9.8)
History of CHF, n (%) 371 (52.4)
IABP, n (%) 254 (35.8)
MI localization, n (%)
Anterior 159 (22.5)
Lateral 197 (27.8)
Inferoposterior 352 (49.7)
Left main CAD 154 (21.7)
Echocardiographic data, mean  SD
LVEF,% 35.8  2.9
EDD, mm 56.0  8.7
ESD, mm 42.5  7.7
EDV, mL 175  29.7
ESV, mL 112  19.2
MR, grade 2.8  0.5
SD, Standard deviation; BSA, body surface area; NYHA, New York Heart Association; COP
vascular disease; PVD, peripheral vascular disease; AF, atrial fibrillation; CHF, congestive
onary artery disease; LVEF, left ventricular ejection fraction; EDD, end diastolic diameter; E
mitral regurgitation.
138 The Journal of Thoracic and Cardiovascular Surgpreoperative volumes, postoperative incidence, and the rate re-
verse remodeling, because these parameters will deeply influence
the outcome, maybe even more than the type of procedure.
And finally let us say that you replace the valve with a biopros-
thesis and the patient benefits from a LV remodeling and survives
long enough for the bioprosthesis to degenerate. This patient now
faces a reoperation for a re-replacement of the mitral valve, which
might have been anticipated by a careful analysis of the preopera-
tive parameters, don’t you think?
Dr Parolari. Concerning the problem of the dimensions, Dr
Dion, I thank you for this question, the problem is that these
data were collected over a 15-year period of time and they were
retrospective. And concerning also the possible predictors of
that, it is very difficult for me to answer this question, but it will
be answered probably much better from the Cardiothoracic Sur-
gery Network in the currently running trial.
About bioprostheses, this is a big problem. We are still investi-
gating that. Hopefully next year, probably Dr Roberto Lorusso,
who is the principal investigator, will have more answers about
that that we don’t have now. Thank you.data in the unmatched population
Replacement (n ¼ 298) Standardized difference
70.3  8.0 1.538
204/94 (68.4/31.6) 0.155
1.75  0.2 0.089
2.9  1.2 0.373
13.9  3.2 0.220
169 (60.0) 0.642
119 (39.9) 0.007
122 (40.9) 0.213
75 (25.1) 0.128
92 (30.7) 0.108
92 (11.7) 0.403
20 (6.7) 0.008
40 (13.3) 0.384
33 (11.0) 0.644
179 (60.0) 0.433
119 (39.9) 0.469
72 (24.1) 0.744
72 (24.1) 0.090
154 (51.6) 0.819
66 (22.1) 0.901
36.6  3.8 0.437
59.0  6.0 1.106
44.2  6.3 0.642
173  28.8 0.369
109  20.1 0.677
3.0  0.5 0.282
D, chronic obstructive pulmonary disease; CRD, chronic renal disease; CVD, cerebral
heart failure; IABP, intra-aortic balloon pump; MI, myocardial infarction; CAD, cor-
SD, end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume;MR,
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